EE12 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab As a First-Line, 12-Month, Fixed Duration Therapy in Chronic Lymphocytic Leukemia (CLL) in Canada

Autor: A Chatterjee, G van de Wetering, R Goeree, C Owen, S Barakat, BS Manzoor, K Sail

Publikováno v: Value in Health. 25:S337

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6c670f2ca3a8b3a6d67ccf7843c28544
https://doi.org/10.1016/j.jval.2022.04.264

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.

Autor: Ghosh N; Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, USA., Eyre TA; Churchill Hospital, Oxford University, Oxford, UK., Brown JR; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Lamanna N; Columbia University, New York, New York, USA., Manzoor BS; AbbVie Inc., North Chicago, Illinois, USA., Coombs CC; University of California Irvine, Irvine, California, USA., Tuncer HH; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ujjani C; Fred Hutchinson Cancer Research Center, Seattle, Washington State, USA., Leslie LA; John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, USA., Roeker LE; CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Davids MS; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Rhodes JM; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Skarbnik AP; Lymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, North Carolina, USA., Sinai W; AbbVie Inc., North Chicago, Illinois, USA., Fleury I; Hôpital Maisonneuve-Rosemont, University of Montreal, Canada., Hill BT; Cleveland Clinic, Cleveland, Ohio, USA., Martinez-Calle N; Nottingham University Hospitals, NHS Trust, Nottingham, UK., Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA., Jawaid D; AbbVie Inc., North Chicago, Illinois, USA., Emechebe N; AbbVie Inc., North Chicago, Illinois, USA., Pearson L; University of Massachusetts, Worcester, Massachusetts, USA., Lansigan F; Dartmouth Cancer Center, Lebanon, New Hampshire, USA., Choi Y; Tufts Medical Center, Boston, Massachusetts, USA., Jensen CE; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Fakhri B; Stanford Cancer Institute, Stanford University, Stanford, California, USA., Stephens DM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Marx SE; AbbVie Inc., North Chicago, Illinois, USA., Schuster SJ; University of Pennsylvania, Philadelphia, Pennsylvania, USA., Coyle M; Lowell General Hospital, Lowell, Massachusetts, USA., Pivneva I; Analysis Group Inc., Montreal, Quebec, Canada., Watson T; Analysis Group Inc., Montreal, Quebec, Canada., Guerin A; Analysis Group Inc., Montreal, Quebec, Canada., Shadman M; Fred Hutchinson Cancer Research Center, Seattle, Washington State, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Dec 19. Date of Electronic Publication: 2024 Dec 19.

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

Autor: Al-Sawaf O; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Robrecht S; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Zhang C; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Olivieri S; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Chang YM; F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada., Fink AM; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Tausch E; Division of CLL, Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany., Schneider C; Division of CLL, Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany., Ritgen M; Universitätsklinikum Schleswig Holstein, Kiel, Germany., Kreuzer KA; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Sivchev L; Multiprofile Hospital for Active Treatment Pazardjik, Pazardzhik, Bulgaria., Niemann CU; Rigshospitalet, Copenhagen, Denmark., Schwarer A; Box Hill Hospital, Box Hill, VIC, Australia., Loscertales J; Hospital De La Princesa, Madrid, Spain., Weinkove R; Te Rerenga Ora Wellington Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital, Wellington, New Zealand.; Cancer Immunotherapy Program, Malaghan Institute of Medical Research, Wellington, New Zealand., Strumberg D; Evangelisches Krankenhaus Herne, Herne, Germany., Kilfoyle A; Palmerston North Hospital, Palmerston North, New Zealand., Manzoor BS; AbbVie Inc, Chicago, IL., Jawaid D; AbbVie Inc, Chicago, IL., Emechebe N; AbbVie Inc, Chicago, IL., Devine J; Genentech Inc, South San Francisco, CA., Boyer M; F. Hoffmann-La Roche Ltd, Welwyn, United Kingdom., Runkel ED; AbbVie Inc, Chicago, IL., Eichhorst B; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Stilgenbauer S; Division of CLL, Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany., Jiang Y; Genentech Inc, South San Francisco, CA., Hallek M; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany., Fischer K; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany.

Publikováno v: Blood [Blood] 2024 Oct 31; Vol. 144 (18), pp. 1924-1935.

Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.

Autor: Ghosh N; Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA., Manzoor BS; AbbVie, Inc., North Chicago, Illinois, USA., Fakhri B; Stanford University, Stanford, California, USA., Emechebe N; AbbVie, Inc., North Chicago, Illinois, USA., Alhasani H; AbbVie, Inc., North Chicago, Illinois, USA., Skarbnik A; Novant Health Cancer Institute, Charlotte, North Carolina, USA., Jawaid D; AbbVie, Inc., North Chicago, Illinois, USA., Shadman M; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Oct; Vol. 205 (4), pp. 1395-1403. Date of Electronic Publication: 2024 Jul 24.

Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.

Autor: Fakhri B; Stanford University, Stanford, CA., Emechebe N; AbbVie, Inc, North Chicago, IL., Manzoor BS; AbbVie, Inc, North Chicago, IL., Jawaid D; AbbVie, Inc, North Chicago, IL., Alhasani H; AbbVie, Inc, North Chicago, IL., Edwards M; Lowell General Hospital, Lowell, MA., Tuncer HH; Dana Farber Cancer Institute, Boston, MA.

Publikováno v: JCO oncology practice [JCO Oncol Pract] 2024 Aug; Vol. 20 (8), pp. 1132-1139. Date of Electronic Publication: 2024 Apr 16.